ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1735

Independent Validation of the Antiphospholipid Score (aPL-S) for the Diagnosis of Antiphospholipid Syndrome (APS)

Savino Sciascia1, Maria Laura Bertolaccini1, Dario Roccatello2 and Munther A. Khamashta3, 1Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 2Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, 3Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: antiphospholipid syndrome, pregnancy, risk assessment and thrombosis

  • Tweet
  • Email
  • Print
Session Information

Title: Antiphospholipid Syndrome

Session Type: Abstract Submissions (ACR)

Background/Purpose: The so called “antiphospholipid score (aPL-S)” was recently developed and validated (1). This score was shown to be a useful quantitative index for diagnosing APS and to be valuable as a predictive marker for thrombosis in autoimmune diseases. We aimed to independently validate the aPL-S by applying the proposed score system to our cohort of SLE patients. (1. Otomo et al. Arthritis Rheum 2012; 64: 504)

Methods: we applied the aPL-S to a cohort of 211 consecutive SLE patients, all attending our Lupus Clinic. aPL-S was calculated for each patient by adding together the points corresponding to the risk factors as described. To validate the aPL-S, we adapted the proposed score using our in house cut-off values for aPL testing as previously reported or according to the current guidelines, as appropriate.  

Results: Overall, 81 patients fulfilled criteria for APS and 73 patients had a history of thrombosis (48 arterial, 41 venous). Out of 144 women who had ever been pregnant, 61 had a history of pregnancy loss. Higher values of aPL-S were seen in patients who experienced thrombosis and/or pregnancy loss when compared to those without clinical events (median 17 [0-86] vs. 4 [0-31], p<0.001).  When analysing clinical subgroups, patients who experienced thrombosis or pregnancy loss showed higher aPL-S compared to those without clinical events (median 18 [0-86] vs. 4 [0-27], p<0.001 for thrombosis; 7 [0-69] vs. 3 [0-29], p=0.029 for pregnancy loss). When the cut-off level for the aPL-S was defined as 30, as per the original study (1) the sensitivity and specificity of the aPL-S were 39% and 95%. The PPV of an aPL-S ≥30 was 36%, whereas the NPV was 91%.

Conclusion: We demonstrated that the aPL profile can be successfully quantified by the aPL-S in an independent cohort of SLE patients. The aPL-S correlated with a history of thrombosis and pregnancy loss in our cohort, suggesting that the aPL-S is a suitable quantitative marker for APS.


Disclosure:

S. Sciascia,
None;

M. L. Bertolaccini,
None;

D. Roccatello,
None;

M. A. Khamashta,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/independent-validation-of-the-antiphospholipid-score-apl-s-for-the-diagnosis-of-antiphospholipid-syndrome-aps/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology